Bioarctic Ab Class B · OMXSTO:BIOA_B
Bioarctic Ab Class B — Q1 2023 Earnings Presentation
22 slides from Bioarctic Ab Class B's earnings presentation, Apr 27, 2023
Slide 1: Q1 Report January-March 2023
BIOARCTIC AB (PUBL) NASDAQ STOCKHOLM: BIOA B Q1 Report January-March 2023 Stockholm, April 27, 2023 Gunilla Osswald, PhD, CEO Jan Mattsson, CFO Tomas Odergren, CMO BioArctic AB
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 3: BioArctic vision: drugs for neurodegenerative diseases
” BioArctic will, through world-leading innovative research, create drugs that improve the lives of patients with neurodegenerative diseases. 3 BioArctic AB
Slide 4: Attractive and well-balanced project portfolio
Attractive and well-balanced project portfolio Regulatory Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 & Market ALZHEIMER’S DSEASE Lecanemab (BAN2401) (Clarity AD) Eisai1 Early Alzheimer’s disease2 Lecanemab (BAN2401) (AHEAD 3-45) Eisai1 Preclinical (asymptomatic) Alzheimer’s diseas
Slide 5: Partnership model to de-risk clinical development and optimize commercialization
Partnership model to de-risk clinical development and optimize commercialization opportunity Alzheimer’s disease Partner track record Discovered and developed world’s best-selling medicine Used to treat confusion for symptoms in Alzheimer’s (dementia) related to disease Alzheimer's disease Industry-
Slide 6: Leqembi has the potential to become the first anti-Aβ antibody with full approval
Leqembi™ (lecanemab) has the potential to become the first anti-Aβ antibody to receive full approval globally USA Japan EU China Granted accelerated Marketing authorization Marketing authorization Initiated Biologics approval Jan 6, 2023 application submitted on application submitted on License Appl
Slide 7: AD/PD held in Gothenburg March - April
AD/PD held in Gothenburg March 28 – April 1 A new era for Alzheimer's disease - Positive atmosphere focused on new treatment opportunities and the progress of blood biomarkers New lecanemab-data presented at the AD/PD congress focused on health-related quality of life outcomes, safety and the unique
Slide 8: AD/PD highlights – Quality of Life results presented
AD/PD highlights – Quality of Life (QoL) results presented QOL-AD (Total Score Subject) • Lecanemab was associated with a relative preservation of health-related quality of life and caregiver burden, as reported by patients and their care partners, with consistent benefits seen across different scal
Slide 9: AD/PD highlights – Tangible differences in daily life activities
AD/PD highlights – Tangible differences in daily life activities for subjects with Alzheimer disease achieved with lecanemab treatment The quality-of-life scale by subject (QOL-AD) showed 56% less decline across 13 sub-domains 9 BioArctic AB
Slide 10: AD/PD highlights – unique binding properties and safety of lecanemab
AD/PD highlights – three presentations on the unique binding properties and safety of lecanemab Lecanemab’s unique binding properties Lecanemab has shown relatively low binding to a specific form of Aβ (CAA fibrils) which potentially explains low frequency of ARIA ARIA With the Use of Antiplatelets
Slide 11: Modelling study shows lecanemab could delay progression 2-3 years
After the period – modelling study shows that lecanemab could delay progression to later stages of disease with 2-3 years Estimated progression time to moderate Alzheimer’s Disease (AD) for patients completing the full lecanemab dosing regime compared with patients subject to standard of care (SOC)
Slide 12: Lecanemab – broad late-stage clinical program
Lecanemab – broad late-stage clinical program Disease stage Early AD Pre-clinical AD MCI Mild AD Moderate AD Severe AD FDA guideline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 Clarity AD Phase 3 confirmatory study AHEAD 3-45 Phase 3 Program – ongoing open-label extension study – ongoing • Eisai
Slide 13: Global estimates for future early AD patients treated with DMTs
Global estimates for future early AD patients treated with disease modifying treatments (DMTs) offer substantial room for growth Eisai estimate 2032: ~240 million Prevalence Early AD Opportunities that could increase patient access: Presents to healthcare • Patient awareness and less stigma • Educat
Slide 14: Financial Summary
Financial Summary 14 BioArctic AB
Slide 15: Operating expenses 2023 within guidance
Operating expenses 2023 within guidance Net Revenues (MSEK) OPEX by item (MSEK) Operating Profit/Loss (MSEK) 301 120 393 96 100 86 132 80 61 218 60 42 45 50 48 42 40 20 -34 -37 -39 -44 -46 -60 7 4 5 4 4 2 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021 2022 2023 2021 2
Slide 16: BioArctic strengthens its financial position
BioArctic strengthens its financial position Cash Balance (MSEK) Cash Flow From Operating Net Result (MSEK) Activities (MSEK) 299 294 1 106 930 892 848 863 137 801 805 752 112 -34 -19 -38 -44 -46 -58 -29 -35 -39 -40 -58 -46 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2021
Slide 17: Upcoming news flow and closing remarks
Upcoming news flow and closing remarks 17 BioArctic AB
Slide 18: Upcoming news flow
Upcoming news flow Q2 2023 Q3 2023 Q4 2023 Q1 2024 Congresses AAIC, Jul 16-20 CTAD, Oct 24-27 AD/PD Mar 5-9 Lecanemab Lecanemab Lecanemab U.S. Advisory U.S. PDUFA & CMS EU & China Committee Jul 6 regulatory response Jun 9 Lecanemab Japan regulatory response Lecanemab s.c. and maintenance dosing U.S.
Slide 19: Thank you Jan Mattsson, and welcome Anders Martin-Löf!
Thank you Jan Mattsson, and welcome Anders Martin-Löf! As of May 1, 2023 Jan Mattsson Anders Martin-Löf VP Finance CFO 19 BioArctic AB
Slide 20: BioArctic: With Patients in Mind
BioArctic: With Patients in Mind Great science Great projects Great partners Great people 20 BioArctic AB
Slide 21: Next report and IR contact
OSKAR BOSSON, VP NEXT REPORT & IR GUNILLA OSSWALD, CEO JAN MATTSSON, CFO COMMUNICATIONS & IR CONTACT • Next Report: Q2 Report Apr-Jun 2023 on July 12, 2023 • Contact: Oskar Bosson, VP Communications & IR +46 704 10 71 80 ir@bioarctic.se To subscribe to financial reports/press releases and for more i
Slide 22: Why invest in BioArctic?
Why invest in BioArctic? Improving life for patients with central nervous system disorders High unmet need for disease-modifying treatments for Alzheimer’s and Parkinson’s diseases creates large commercial opportunity World-class research and development driven organization with basis in founder’s b